Altered intestinal bile salt biotransformation in a cystic fibrosis (Cftr(-/-)) mouse model with hepato-biliary pathology by Bodewes, Frank A. J. A. et al.
  
 University of Groningen
Altered intestinal bile salt biotransformation in a cystic fibrosis (Cftr(-/-)) mouse model with
hepato-biliary pathology
Bodewes, Frank A. J. A.; van der Wulp, Mariette Y. M.; Beharry, Satti; Doktorova, Marcela;
Havinga, Rick; Boverhof, Renze; Phillips, M. James; Durie, Peter R.; Verkade, Henkjan J.
Published in:
Journal of Cystic Fibrosis
DOI:
10.1016/j.jcf.2014.12.010
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2015
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Bodewes, F. A. J. A., van der Wulp, M. Y. M., Beharry, S., Doktorova, M., Havinga, R., Boverhof, R., ...
Verkade, H. J. (2015). Altered intestinal bile salt biotransformation in a cystic fibrosis (Cftr(-/-)) mouse
model with hepato-biliary pathology. Journal of Cystic Fibrosis, 14(4), 440-446.
https://doi.org/10.1016/j.jcf.2014.12.010
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the











Journal of Cystic Fibrosis 14 (2015) 440–446Altered intestinal bile salt biotransformation in a cystic
fibrosis (Cftr−/−) mouse model with hepato-biliary pathology
Frank A.J.A. Bodewes a,⁎, Mariëtte Y.M. van der Wulp a, Satti Beharry b, Marcela Doktorova a,
Rick Havinga a, Renze Boverhof a, M. James Phillips b, Peter R. Durie b, Henkjan J. Verkade a
a Pediatric Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, PO Box 30001, 9700 RB Groningen,
The Netherlands
b Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, 555 University Ave, Toronto, ON M5G 1X8, Canada
Received 29 January 2014; revised 15 December 2014; accepted 16 December 2014
Available online 27 January 2015Abstract
Background: Cftr−/− tm1Unc mice develop progressive hepato-biliary pathology. We hypothesize that this liver pathology is related to alterations in
biliary bile hydrophobicity and bile salt metabolism in Cftr−/−tm1Unc mice.
Methods:We determined bile production, biliary and fecal bile salt- and lipid compositions and fecal bacterial composition of C57BL/6 J Cftr−/−tm1Unc
and control mice.
Results:We found no differences between the total biliary bile salt or lipid concentrations of Cftr−/− and controls. Compared to controls, Cftr−/− mice
had a ~30% higher bile production and a low bile hydrophobicity, related to a ~7 fold higher concentration of the choleretic and hydrophilic bile salt
ursocholate. These findings coexisted with a significantly smaller quantity of fecal Bacteroides bacteria.
Conclusions: Liver pathology in Cftr−/−tm1Unc is not related to increased bile hydrophobicity. Cftr−/− mice do however display a biliary phenotype
characterized by increased bile production and decreased biliary hydrophobicity. Our findings suggest Cftr dependent, alterations in intestinal
bacterial biotransformation of bile salts.
© 2014 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Cystic fibrosis; Liver disease; Bile salts; Ursocholic acid; Mice model; Intestinal bacterial microflora; CFTR1. Background
The pathogenesis of cystic fibrosis related liver disease (CFLD)
is not known (1,2). Most information, on CFLD in humans, has
been derived from post-mortem evaluations (3). Liver histology
shows a biliary cirrhosis with bile duct proliferation and damage
pointing in the direction of a biliary origin of the disease (1,3).
Prospective histological studies in humans are scarce, mainlyF, Cystic fibrosis; Cftr, Cystic fibrosis transmembrane
or; CFLD, Cystic fibrosis related liver disease; Unc,
Carolina; CA, Cholic acid; DCA, Deoxycholic acid;
ycholic acid; HDCA, Hyodeoxycholic acid; UDCA,




ublished by Elsevier B.V. on behalf of European Cystic Fibrosbecause of the need for invasive diagnostic procedures in
asymptomatic patients (4).
Animal models can, theoretically, help to explain how liver
disease in CF develops.Most CFmouse models do not display any
liver pathology (5). However, the C57BL/6 J Cftr−/−tm1Unc mice
offers the opportunity to study liver disease, since it does show,
progressive, CF like liver pathology, with increasing age, that is not
present control mice (6). Additionally, Freudenberg et al. reported
that older ΔF508 CF mice (background 75% C57BL/6, 25%
129SvEv) also had more liver fibrosis than their wild-type controls
(7). The fact that these ΔF508 CF mice only develop a liver
phenotype at a very high age (100–200 days) makes them less
suitable to study CFLD development.
Biliary bile salt hydrophobicity and cytotoxicity are frequently
involved in the development of cholestatic liver diseases (8).is Society.
441F.A.J.A. Bodewes et al. / Journal of Cystic Fibrosis 14 (2015) 440–446Primary bile salts are synthesized in the liver and are secreted,
via the bile, into the intestine. In the gut, primary bile salts are
transformed to secondary bile salts by the intestinal microflora.
Differences in intestinal bacterial flora composition induce
variations in bile salt composition. After passage through the gut,
most bile salts are absorbed in the terminal ileum and return to
the liver as part of the enterohepatic circulation (9).
As a result of the intestinal biotransformation, a variety of bile
salts is formed. Individual bile salts have variable physiological
properties. Hydrophobic bile acids are more cytotoxic than
hydrophilic bile salts. On the other hand, when secreted into bile,
hydrophilic bile salts are more choleretic than hydrophobic bile
salts. The cytotoxicity of biliary bile salts is determined by their
concentration, their composition and the presence of additional
biliary lipids like phospholipids.
We hypothesized that an increased biliary bile salt hydropho-
bicity (and thus, cytotoxicity) plays a role in the early genesis of
the liver pathology of the Cftr−/−tm1Unc mice. To address this
hypothesis, we characterized bile production and biliary and fecal




All experimental protocols were conducted in the Hospital for
Sick children, the Research Institute, Toronto, Canada, after
approval by the institutional Animal Care Committee. Mice were
bred to wild-type C57BL/6 J mice, obtained from the Jackson
Laboratories (Bar Harbor, ME). To minimize bowel obstruction
and optimize long-term viability, 20- to 23-day-old congenic
C57BL/6 J Cftr−/−tm1Unc mice and their Cftr+/+ littermates were
weaned to a liquid diet (Peptamen, Nestlé Nutrition, Canada).
Mice were housed in a non-sterile conventional housing unit in
micro-isolators cages, with corncob bedding changed daily, and
provided with sterile water in addition to the liquid diet. The
colony was maintained at a pathogen-free status by serological
screening at a commercial laboratory. The animals used for the
experiments were approximately 1.5–4 months old.
2.2. Experimental procedures
All experiments were performed in mice from the same
colony. We used Cftr−/− mice (N = 9, four males) and control
mice (N = 9, three males). At the start of the experiment, mice
were housed in metabolic cages. The total fecal production
of individual mice was collected for three consecutive days,
dried and homogenized. After overnight fasting, bile was
collected after prior surgical ligation of the common bile duct
and gall bladder cannulation using silicone tubing (size
0.020″ × 0.037″, Degania Silicone Ltd.) under anesthesia.
The anesthetic mixture consisted of: 0.75 ml ketamine
(100 mg/ ml), 0.25 ml xylazine (20 mg/ ml) and 4 ml saline.
The mixture (0.1 ml per 10 gram body weight) was intraperito-
neally administered. Body temperature was maintained by
placement of the animal in a temperature and humidity controlledincubator. After a 10 minutes equilibration period, bile secretions
were collected in 3 periods of 30 minutes. Bile flow rate was
assessed gravimetrically, assuming that 1 g of secretion corre-
sponds to 1 ml. The mice were euthanized after the bile collection,
and the liver was harvested.
2.3. Liver histology
Hematoxylin and eosin (H&E) slices of the whole liver were
assessed in a blinded fashion by an expert hepato-pathologist (JP)
for the degree of portal inflammation, bile duct changes and
bridging fibrosis. We applied a previously published numerical
scoring system for each parameter, using an arbitrary 0 to 4 scale,
in which zero represents normal histology, and four represents the
most severe pathology for each parameter (6). Aminimum of five
portal tracts was assessed for each mouse, and an average of the
numerically scored parameters provided a total overall score for
each animal.
2.4. Analytical techniques
Biliary BS concentrations in bile and feces were determined
by an enzymatic fluorimetric assay (10). Lipids were extracted
from the bile (11). The phospholipid and cholesterol concentra-
tions were determined using a spectrophotometric assay (12).
Biliary BS composition in bile collected in first 30 minute
period) and in feces were determined by extracting the bile salts
with commercially available Sep-Pak-C18 (Mallinckrodt Baker,
Deventer, The Netherlands) cartridges and converting them to
their methyl ester/trimethylsilyl derivatives (13). Bile salt profiles
were analyzed using capillary gas chromatography. The hydro-
phobicity of BS in bile was calculated according to the Heuman
index based on the fractional contribution of the major BS species
(14).
2.5. Bacterial DNA
Bacterial DNA was isolated from 150 mg of dried homoge-
nized feces by commercially available QIAamp DNA Stool Mini
Kit (Qiagen, Valencia, CA). Concentration of bacterial DNAwas
measured by spectrophotometry (NanoDrop 2000c, Thermo
Scientific, Wilmington, DE) and 50 ng (15 ng respectively for
universal primer) of DNAwas used for amplification by RT-PCR
with SensiMix™ SYBR® Hi-ROX Kit (Bioline, Taunton, MA)
using bacterial groups specific primers for 16S (supplementary
materials: Table 1).
2.6. Statistical analysis
Analyses were performed using IBM SPSS Statistics
version 22 (IBM corp., United states). All quantitative results
are reported as means ± SEM and ordinal results as means
with range. Differences between study groups were evaluated
using the Mann-Whitney U test. Bile flow was additionally
analyzed by correlation and regression analysis. The level of
significance was set at a P value of less than 0.05.
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3.1. Histology
The mean age of the Cftr−/− and control mice was similar
(75 ± 25 days). We found a significantly higher presence of bile
duct changes (Cftr−/−: 0.7 (range: 0–2) vs.Cftr+/+: 0.1 (range: 0–
1); respectively; P b 0.05) and bridging fibrosis (Cftr−/−: 1.1
(range: 0–4) vs. Cftr+/+: 0; respectively; P b 0.05) in Cftr−/−
mice compare to controls. However, histology did not differ
between Cftr−/− mice and controls with respect to portal
inflammation (Cftr−/−: 1.5 (range: 0–4) vs. Cftr+/+: 0.5 (range:
0–2); respectively; NS). Our current histological findings were,
to a large extent, consistent with the previously reported liver
pathology in this mouse model (6).3.2. Bile production and bile salt secretion
We found that the bile production was 20–30% higher in
Cftr−/− mice compared to controls (P b 0.05 in the last sample
period, Fig. 1A). The total biliary bile salt concentration and total
biliary bile salt secretion rate were not different between Cftr−/−
mice and controls (Fig. 1B and 1C). Bile salt-dependent flow and
bile salt independent flow were derived. Regression analysis
showed a similar bile salt independent bile flow (y-intercept) for
both groups (1.8 ± 0.7 vs. 3.2 ± 0.6 ml.min−1.100 gram BW−1,
respectively; NS). In contrast, the bile salt-dependent flow (slope)Fig. 1. Bile production and bile salt secretion parameters of Cftr+/+ and Cftr−/− m
and bile salt secretion rate (BSSR) vs. bile flow in Cftr knockout mice (Cftr−/−) and c
BSSR vs. bile flow data within both groups. Here there is a significant correlation bet
as in Cftr−/− mice (Spearman’s Rho = 0.762, P = 0.000). Data are presented as meawas significantly higher in Cftr−/− mice compared to controls
(20 ± 3 vs. 8 ± 3 μL/μmol, respectively; P b 0.05) (Fig. 1D).
3.3. Biliary bile salt profile
In their bile, Cftr−/− mice had significantly lower proportions
of CA (40.3 ± 8.5 vs. 53.0 ± 7.5%; p b 0.05), DCA (1.6 ± 2.0
vs. 5.3 ± 2.7%; p b 0.05) and ω-MCA (0.9 ± 0.5 vs. 6.1 ±
2.6%; P b 0.05) compared to controls (Fig. 2A). The proportion
of biliary primary bile salts (CA, CDCA, α- and β-MCA) was
significantly decreased in Cftr−/− mice compared to controls
(70% vs. 84% respectively; p b 0.05, Fig. 2B). Additional gas
chromatographic analysis of bile showed an unexpected, ~7-fold
higher content of the secondary bile salt UCA in Cftr−/− mice
compared to controls (24.6 vs. 3.3% respectively; P b 0.01,
Fig. 2A). Mass spectrometry confirmed the identification and
abundance of UCA in CF mice. As a result of the increased
proportion of the hydrophilic UCA, the biliary bile salt
hydrophobicity index of Cftr−/− mice was significantly lower
compared to controls (-0.25 ± 0.09 vs. -0.13 ± 0.05 respectively;
P b 0.05; Fig. 2C). We tested whether the severity of liver
pathology correlated with our current bile acid data but did not
find a significant correlation.
3.4. Biliary lipids profile
There was no significant difference between the biliary
phospholipid concentration of Cftr−/− and control mice (Fig. 3A).ice. Biliary bile flow (A), bile salt concentration (B) bile salt secretion rate (C)
ontrol littermates (Cftr+/+). Panel D shows the correlation between all individual
ween BSSR and bile flow in Cftr+/+ (Spearman’s Rho 0.394, P = 0.042), as well
ns ± SEM of n = 9 mice per group. *P-value b 0.05.
Fig. 2. Biliary bile salt profile of Cftr+/+ and Cftr−/− mice. Biliary bile salt profiles (A). Abbreviations: CA = cholic acid, DCA = deoxycholic acid, CDCA =
chenodeoxycholic acid, HDCA = hyodeoxycholic acid, UDCA = ursodeoxycholic acid, UCA = ursocholic acid, MCA = muricholic acid. Data are presented as a
percentage of different bile salt species (n = 6–7 mice per group). Relative distribution between primary bile salt content and secondary bile salt (B). Primary bile salt
content is decreased in Cftr−/− mice, whereas secondary bile salt content is increased (P = 0.004). Heuman index (C) of the total biliary bile salts representing the
hydrophobicity of bile salts.
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linearly related to the bile salt secretion rate, despite the
significant differences in biliary bile salt hydrophobicity
(Fig. 3B). We found no difference in the biliary phospholipid to
bile salt ratio between Cftr−/− and control mice (Fig. 3C), nor in
biliary cholesterol concentration or cholesterol secretion rate
(data not shown).
3.5. Fecal bile salt composition
The fecal bile salt loss of Cftr−/− mice was ~80% higher
compared to controls (Fig. 4A). Mass spectrometry analysis
showed that, in correspondence with the biliary bile salt profile,
Cftr−/− mice also had a profoundly higher fecal UCA content
compared to controls (27 vs. 1%, respectively; P b 0.01, Fig. 4B).
In feces, Cftr−/− mice had a significantly lower DCA (11.4 ± 10.3
vs. 42.0 ± 10.7% respectively; P b 0.01), HDCA (0.3 ± 0.2 vs.
2.2 ± 0.9% respectively; P b 0.01) and ω-MCA (1.2 ± 0.9 vs.
18.1 ± 8.3 respectively; P b 0.01) content compared to controls.
On the other hand, Cftr−/− mice had a significantly higher fecal
CA content compared to controls (26.5 ± 9.1% vs. 8.4 ± 7.4%
respectively; P b 0.01).
To address whether the observed differences in bile salt
composition were genotype or environment (microflora) related,
we performed fecal bile salt analysis in mice of C57BL/6 J Cftr−/−Fig. 3. Biliary phospholipid of Cftr+/+ and Cftr−/− mice. Phospholipid concentratio
to bile salt ratio (C) in Cftr knockout mice (Cftr−/−) and control littermates (Cftr+/+)
mice per group.mice and controls from a different colony at another institution
(courtesy of Dr. R.C. De Lisle, University of Kansas, Kansas City,
Missouri; N = 5 per group). We found that the bile salt
composition, in particular the presence of UCA in CF mice, was
largely identical (data not shown).
3.6. Bacterial composition of fecal flora
We found no difference in the total fecal bacterial DNA
content between Cftr−/− and controls. We found a significant
decrease of in the fecal Bacteroides content in Cftr−/− mice
compared to controls (1.1 ± 0.4).108 vs. (1.6 ± 0.3).107 bacteria/
gram feces respectively; P b 0.01, Fig. 5A). No differences were
observed in fecal Clostridium or Lactobacilli content between
Cftr−/− mice and controls (Figs. 5B and 5C).
4. Discussion
We hypothesized that the C57BL/6 J CF Cftr−/−tm1Unc mice
develops hepatic histopathology in the context of a hydrophobic
and cytotoxic biliary bile salt profile. In contrast to our
assumptions, we actually found that the bile of Cftr−/−tm1Unc
mice was more hydrophilic and that the bile production in
Cftr−/−tm1Unc mice, was in fact higher than in control mice. We
assume that the higher bile production is related to the increasedn (A) the phospholipid secretion vs. bile salt secretion rate (B) and phospholipid
, n = 9 mice per group. If appropriate data presented as means ± SEM of n = 9
Fig. 4. Fecal bile salt excretion and fecal bile salt profile of Cftr+/+ and
Cftr−/−mice. Total bile salt excretion (A), presented as means ± SEM. Bile salt
profiles (B), data are presented as a percentage of different bile salt species
present in bile. Abbreviations: CA = cholic acid, DCA = deoxycholic acid,
CDCA = chenodeoxycholic acid, HDCA = hyodeoxycholic acid, UDCA =
ursodeoxycholic acid, UCA = ursocholic acid, MCA = muricholic acid. n = 9
mice per group. *P-value b 0.05.
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This conclusion is supported by the significantly higher bile
salt-dependent bile flow, found in the Cftr−/− mice.
Other mechanisms for the development of liver pathology in
the Cftr−/−tm1Unc have been suggested. Blanco et al. describe
that chemical induction of colitis, by dextran, aggravated bile
duct injury in Cftr−/−tm1Unc mice compared to controls (16). In a
in a follow-up study they describe a decreased peroxisome
proliferator-activated receptor alpha expression in Cftr−/−tm1Unc
(17). Different from our bile salt hydrophobicity hypothesis,
their findings point more towards a Cftr related, immunologic/
inflammatory genesis of CFLD.
The increased UCA enrichment in bile and feces of Cftr−/−
mice is an unexpected and notable finding. UCA is formed, inFig. 5. Fecal bacterial content of Cftr+/+ and Cftr−/− mice. Fecal content (bacteria
(C) based on microbial DNA measurement. Data are presented as means ± SEM ofthe intestine, by the bacterial transformation of CA. In normal
conditions, UCA is rapidly transformed to DCA, by the bacterial
microflora. As a result the contribution of UCA to the bile salt
pool, is usually very small. The high UCA enrichment of bile and
feces found in the Cftr−/−tm1Unc mice is, therefore, the related to,
Cftr dependent, alteration in the bacterial microflora normally
involved in the transformation of CA to DCA.
Elaborating on that subject, we indeed observed significant
differences in the intestinal bacterial composition between
Cftr−/− and control mice. In particular we demonstrated that the
contribution of Bacteroides bacteria was significantly lower in
feces of Cftr−/− mice. Bile salt deconjugation activity is found
in many bacterial species including Bacteroides. As a result of
this observation, difference in Bacteroides content, could
theoretically, be related to the observed variation in biliary
and fecal bile salt composition. However, we realize that our
results, on fecal bacterial composition, do not prove causality in
this matter.
We found comparable differences in bile salt composition
between Cftr−/−tm1Unc and control mice, housed in a different
animal facility. These results suggest a reasonable reproduc-
ibility of our findings. Nevertheless, we realize, the Cftr/bile
salt/microflora interaction is probably not a genotype related,
fixed condition. The latter is illustrated by our previous study
with C57BL/6 J CF mice (18). In this study we did not see any
fecal UCA, despite the fact that the mice were bred and fed
under the same conditions.
Our current results, in the Cftr−/−tm1Unc mice model, differ in
several aspects from the results found in human studies on bile salt
metabolism and composition, in CF. Strandvik et al. described
an increase of the primary bile acids in urine and serum of CF
patients. They reported a correlation between the serum bile salt
composition and the extent of liver disease in cystic fibrosis.
However, different from our current findings in mice, they do
describe a predominance of primary bile salt species. They suggest
their findings to be related to specific changes of intestinal factors
in CF conditions. Smith et al. described the duodenal, urinary and
serum bile salt compositions of CF patients with and without
CFLD (19). They report a reduction of secondary bile salts in CF
patients compared to healthy controls. Based on their results,
these researchers propose a role of secondary, more hepatotoxic,
bile salts in the pathogenesis of CFLD.
UCA is a naturaly occurring, highly choleretic bile salt. In our
model, the enrichment of UCA, leads to a significantly increased
bile salt-dependent flow and to a low biliary hydrophobicity inper gram feces) of Bacteroides (A) Lactobacillus (B) and Clostridium coccoides
n = 6–9 mice per group. *P-value b 0.05.
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decrease biliary excretion of phospholipid and cholesterol in
rats (20). However, in our current study we did not see UCA
effects on the biliary phospolipid and cholesterol excretion. It is
notable that, in this study, we did find any ursodeoxycholic
acid (UDCA) in either bile or stools. Different from our current
results, we did see low amounts of UDCA (b5% of total)
in another Cftr knockout mouse model (Cftr−/− tm1CAM) (21).
The presence of UDCA in CF conditions may, therefore, be
strain-specific. Additionally, in humans, Smith et al. reported
significantly greater proportions of endogenous ursodeoxycholic
acid in bile of CF patients without liver disease when compared to
CF subjects with liver disease (19). Their results imply a possible
protective role, of endogenous UDCA, in the development of
CFLD.
The fact that, the mice in this study were exclusively fed a
liquid diet (Peptamen) may have influenced bile salt composition
results. The Cftr−/−tm1Unc mice remain dependent on liquid
feeding, to prevent lethal intestinal obstruction (22). Cftr−/− mice
and controls were both fed the liquid diet. Therefore, in itself, the
liquid diet cannot directly explain the differences in bile salt
composition between Cftr−/− mice and controls. On the other
hand, it cannot be excluded that there are differences in the way,
Cftr−/− and control mice interact with the liquid diet, for example,
on the level of the intestinal bacterial microflora. In this manner,
theoretically, a liquid diet could, indirectly, result in differences in
bile salt composition.
We found an increased fecal bile salt excretion in Cftr−/−tm1Unc.
Fecal bile salt loss is an intrinsic and consistent phenotype
of human CF patients as well as of experimental CF animal
models (23,24). In a previous study, we saw that intestinal bile
salt loss in Cftr−/− mice is compensated by an increased hepatic
bile salt synthesis (21). It has been suggested that the underlying
mechanism of increased fecal bile salt excretion involves
increased fecal fat excretion in CF conditions (25). However,
previously we reported that increased fecal bile salt loss was also
observed in CF mice without fat malabsorption (26). Theoreti-
cally, an increased transit time could be related to the increased
fecal bile salt output. However, CFmice have formed, solid, stool
and do not present with diarrhea. Additionally we did not find any
indication for an altered intestinal transit time of dietary lipids in
ΔF508-CFmice, compared to wild type mice, despite a similarly,
increased, fecal bile salt excretion in ΔF508-CF mice as in
Cftr−/−tm1Unc mice (24).
In our current study we found that the hepato-biliary
pathology of Cftr−/−tm1Unc mice is not related to increased
biliary bile salt hydrophobicity or cytotoxicity. However,
Cftr−/−tm1Unc mice do display distinctive changes in the
metabolism and enterohepatic circulation of the bile salts.
Recent discoveries in the intestinal regulation of bile salt
synthesis shed a new light on the importance and role of
the intestinal bile salt composition. The reported differences
in bile salt metabolism indicate a Cftr-dependent influence
on intestinal bacterial microflora and microbial bile salt
metabolism. These conclusions are supported by the fact that
our findings coexisted with a significant smaller quantity of
fecal Bacteroides bacteria. It is tempting to speculate that theseprocesses play a role in the development of the CF intestinal and
hepatic phenotype.Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2014.12.010.References
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